Alexza Pharmaceuticals Inc., of Mountain View, Calif., appointed Winston R. Brown Jr. vice president, quality.

Alzheon Inc., of Lexington, Mass., appointed Franz F. Hefti to its board.

Amag Pharmaceuticals Inc., of Waltham, Mass., added James R. Sulat to its board, and named Gino Santini board chairman.

Astellas US LLC, a subsidiary of Tokyo-based Astellas Pharma Inc., named Jeffrey D. Bloss senior vice president, medical affairs Americas, Astellas scientific and medical affairs.

Dyax Corp., of Burlington, Mass., appointed Todd Bazemore executive vice president and chief commercial officer.

Hydra Biosciences Inc., of Cambridge, Mass., named Bertrand (Bert) Chenard senior vice president, chemistry, pharmacology and preclinical development, and Magdalene Moran senior vice president, biology.

Intrexon Corp., of Germantown, Md., added James S. Turley to its board.

Kolltan Pharmaceuticals Inc., of New Haven, Conn., appointed Daniel R. Vlock to its board, and added William S. Slattery as a board observer.

Nanobiotix SA , of Paris, named Thierry Otin head of manufacturing and supply and he will be responsible for the manufacturing plans to move the lead product, NBTXR3, from clinical trials into full commercialization.

Rich Pharmaceuticals Inc., of Beverly Hills, Calif., appointed Richard L. Chang to its medical advisory board.

Shire plc, of Dublin, appointed Robert Dempsey vice president of its emerging eye care franchise. He will be based in Lexington, Mass.

Tokai Pharmaceuticals Inc., of Cambridge, Mass., named Karen J. Ferrante head of R&D and chief medical officer.

Transtech Pharma LLC, of High Point, N.C., appointed Stephen L. Holcombe president of Transtech and its sister company High Point Pharmaceuticals LLC.

Xbiotech Inc., of Austin, Texas, named Robert Lindsey senior vice president corporate development and general counsel.